| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -10,806 | -8,291 | -10,370 | -2,402 |
| Income tax benefit (expense) | 5 | -3 | 5 | -3 |
| Net loss | -10,811 | -8,288 | -10,375 | -2,399 |
| Series a preferred stock conversion inducement | 18,516 | - | - | - |
| Deemed dividend related to seriesa preferred stock conversion | 11,947 | - | - | - |
| Undeclared dividends on series a preferred stock | 0 | 714 | 712 | 803 |
| Net loss attributable to common stockholders | -41,274 | -9,002 | -11,087 | -3,202 |
| Net loss per common share, basic (in dollars per share) | -0.96 | -0.27 | -0.39 | -0.12 |
| Net loss per common share, diluted (in dollars per share) | -0.96 | -0.27 | -0.39 | -0.12 |
| Weighted average common shares outstanding, basic (in shares) | 43,057,632 | 32,899,297 | 28,527,453 | 26,501,597 |
| Weighted average common shares outstanding, diluted (in shares) | 43,057,632 | 32,899,297 | 28,527,453 | 26,501,597 |
TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. (TLSI)